healthy volunteers
Conditions
Interventions
Two-step study. In the first, there will be 12 healthy adult individuals of both sexes. Volunteers will participate in two groups acutely - one intervention day in each, with a seven-day interval betw
in the 2nd test) 1000 mg caffeinated instant coffee (Nescafé®) diluted in 50 ml water
in the 3rd test) 300 mg of caffeine (handled in pharmacy) diluted in 50 ml of water
in the 4th test) half bitter powdered chocolate (Nestlé®) diluted in 50 ml of water. Placebo: n = 12 will perform mouthwash for 10 seconds at the start of the race. In the 1st test) 50 ml of the juice
in the 2nd test) 1000 mg of decaffeinated instant coffee (Nescafe®) diluted in 50 ml of water
in the 3rd test) 300 mg cornstarch diluted in 50 ml water
in the 4th test) carob powder (Nestlé®) diluted in 50 ml of water. Blood samples will be collected and performance, blood pressure and hydration will be measured before the intervention and after a 10
Dietary supplement
Other
SP6.051.227
G11.427.410.698.277
Sponsors
Faculdade de Nutrição da Universidade Federal de Goiás
Faculdade de Nutrição da Universidade Federal de Goiás
Eligibility
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: First stage: healthy adult men; healthy adult women; have been training triathlon for over a year; aerobic capacity greater than 60% of VO2max; have a fixed routine of intense and moderate exercise (ranging from 4-6 times per week with a duration of 60-240 min per training day). Second stage: healthy adult males; CrossFit® practitioners for at least one year.
Exclusion criteria
Exclusion criteria: First and second steps: use of anabolic steroids; use of dietary supplements; use of immunosuppressive drugs; use of antibiotics; use of stereochemical and non-stereochemical anti-inflammatories; in a food restriction program; carriers of immune diseases; hepatic diseases; renal diseases; pneumopathy; cardiopathies; chronic alcoholics; smokers; injured individuals; individuals in the inflammatory process.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| First stage: reduction in performance time of 10-km race, measured by timing, from the 5% variation in relation to placebo. ;Second stage: increase in total number of repetitions of all exercises during the 60-minute training session, evaluated by series count and repetitions, from the 5% variation over placebo. | — |
Secondary
| Measure | Time frame |
|---|---|
| First stage: maintenance of serum concentrations of inflammatory cytokines, C-reactive protein, glycemia and lactate from the non-variation of the values in relation to the placebo group, evaluated by the ELISA method in the pre- and post-race of 10-km. ; Second stage - expected secondary outcome 1: attenuation of muscle power loss immediately after and 24 hours after the training session compared to the initial time from the 5% variation when compared to the placebo treatment, evaluated by means of a linear transducer of velocity in the pre, post and 24 hours after the training session.;Second stage - expected secondary outcome 2: attenuation of muscle pain upon palpation and stretching, immediately after and 24 hours after the training session, relative to the initial time from the 5% variation when compared to the placebo treatment, as assessed by visual analog scale at pre, post, and 24 hours after the training session.;Second stage - expected secondary outcome 3: lower elevations in the concentrations of the immunometabolic markers (creatine kinase, C-reactive protein, lactate and glycemia) immediately after and 24 hours after the training session, relative to the initial time from the 5 % when compared to the placebo treatment, evaluated by means of analyzes of serum concentrations at the pre, post and 24 hours after the training session. | — |
Countries
Brazil
Contacts
Public ContactGustavo Pimentel
Universidade Federal de Goiás
Outcome results
None listed